← Back to Search
CNS Drug Delivery For Diseases Eradication: An Overview
Anil Kumar Kalvala, P. Giri, Jyothirmai Kaligatla, Wahid Khan, A. Kumar
Published 2017 · Medicine
Download PDFAnalyze on Scholarcy
Central nervous system (CNS) diseases lead to severe disability and account for considerable amount of health burden globally making them one of the most devastating diseases affecting the mankind. Though new drugs to eradicate CNS diseases are much warranted, drug development in this field is going at snail’s pace due to potential limitation of low success rate in clinical trials. Therapeutic delivery to the brain offers superior challenge to scientific community because of the presence of blood brain barrier (BBB), the lipophilic barrier which hampers the entry of foreign substances into brain and drug efflux transporters which prevents drug accumulation in CSF (Cerebro spinal fluid). Further it is assumed that BBB permeability and brain pharmacokinetics alters with pathological condition which further complicates the drug delivery. In view of this altered physiology, scientists have designed some pharmaceutically active formulations of drug molecules which can lodge in brain because of their altered lipophilicity, selective permeability or ligand based targeting. Such delivery options enhance the efficient delivery of active therapeutic molecules to the target of interest without showing any side effects. Such site directed target delivery also ensures improved brain pharmacokinetics of the compounds. This book chapter offers information about myriad range of CNS diseases; unmet needs in their management and several novel methods of CNS directed delivery options for therapeutics to alleviate those nervous disorders with maximum efficacy. In particular by realizing the emergence of nano technology and nano medicine, we have discussed nano technology based formulations and their potential importance for CNS delivery in detail.
This paper references
The cost of biopharmaceutical R&D: is biotech different?
J. DiMasi (2007)
Drug delivery to the central nervous system: a review.
A. Misra (2003)
From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment
B. Moghaddam (2012)
Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns
J. Sánchez-Mut (2016)
De novo mutations in schizophrenia implicate synaptic networks
M. Fromer (2014)
Nanoparticles for Targeted Delivery of Antioxidant Enzymes to the Brain after Cerebral Ischemia and Reperfusion Injury
Xiang Yun (2013)
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
J. Huse (2010)
Polymeric nanoparticles for drug delivery to the central nervous system.
T. Patel (2012)
Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder.
K. Lewandowski (2011)
Neuroimaging and plasticity in schizophrenia.
A. Meyer-Lindenberg (2014)
Development of Lipid Based Nanoparticulate Drug Delivery Systems and Drug Carrier Complexes for Delivery to Brain
S. Salunkhe (2015)
Nanoparticles for Brain Drug Delivery
M. Masserini (2013)
Infrared multiphoton microscopy: subcellular-resolved deep tissue imaging.
V. Andresen (2009)
Comprehensive mental health action plan 2013-2020.
S. Saxena (2015)
WHO classification of tumours of the central nervous system
D. N. Louis (2007)
Ultrasound-mediated blood-brain barrier disruption for targeted drug delivery in the central nervous system.
Muna Aryal (2014)
Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge
M. Busquets (2015)
Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats.
B. Boyd (2006)
Erratum to “Use of Metarhizium anisopliae Chitinase Genes for Genotyping and Virulence Characterization”
S. Niassy (2014)
Carboxyfullerenes as neuroprotective agents.
L. Dugan (1997)
Fullerenes: An introduction and overview of their biological properties
S. Thakral (2006)
Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences
Z. Redzic (2010)
Novel Central Nervous System Drug Delivery Systems
Jocelyn Stockwell (2014)
Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma Treatment
Pedro M. M. Costa (2013)
MicroRNAs as biomarkers for CNS cancer and other disorders
E. D. Smaele (2010)
Nanostructures of hydrated C60 fullerene (C60HyFn) protect rat brain against alcohol impact and attenuate behavioral impairments of alcoholized animals.
A. Tykhomyrov (2008)
Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial
C. Holmes (2008)
Chlorotoxin-conjugated nanoparticles as potential glioma-targeted drugs
Yuejun Fu (2011)
Parkinson’s disease: From human genetics to clinical trials
M. P. van der Brug (2015)
Solid lipid nanoparticles for potential doxorubicin delivery in glioblastoma treatment: preliminary in vitro studies.
Luigi Battaglia (2014)
Nanotoxicity: the growing need for in vivo study.
H. C. Fischer (2007)
Magnetic nanoparticles for theragnostics.
V. Shubayev (2009)
Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.
H. Uchino (2002)
What are the functional consequences of neurocognitive deficits in schizophrenia?
M. Green (1996)
Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression.
S. Haque (2014)
NEUROSCIENCE. Alzheimer's amyloid theory gets modest boost.
E. Underwood (2015)
Nano-ART and NeuroAIDS
M. Das (2016)
Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.
Howard E. Gendelman (2015)
Cancer nanotechnology: opportunities and challenges
M. Ferrari (2005)
Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders
R. Carroll (2010)
DopAmide: Novel, Water‐Soluble, Slow‐Release l‐dihydroxyphenylalanine (l‐DOPA) Precursor Moderates l‐DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons
D. Atlas (2016)
Prodrugs targeting the central nervous system (cns)
Falasteen Salameh (2015)
Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI‐guided focused ultrasound
Lisa Treat (2007)
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S. Miyamoto (2012)
The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches
J. Lieberman (2001)
Solid lipid nanoparticles for targeted brain drug delivery.
P. Blasi (2007)
Research confuses me: what is the difference between case-control and cohort studies in quantitative research?
S. F. Higgins (2013)
The scavenging of reactive oxygen species and the potential for cell protection by functionalized fullerene materials.
J. Yin (2009)
Blood-brain barrier drug targeting: the future of brain drug development.
W. Pardridge (2003)
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size.
H. Cabral (2011)
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.
Q. Ostrom (2014)
Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease
E. Goetzl (2015)
Prediction and prevention of psychosis in youth at clinical high risk.
J. Addington (2012)
The Poorly Membrane Permeable Antipsychotic Drugs Amisulpride and Sulpiride Are Substrates of the Organic Cation Transporters from the SLC22 Family
J. N. Dos Santos Pereira (2014)
Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles
R. Alyautdin (2004)
Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB
K. Nagpal (2013)
Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats
DP-155, a lecithin derivative of indomethacin, is a novel nonsteroidal antiinflammatory drug for analgesia and Alzheimer's disease therapy.
E. Dvir (2007)
Liposome targeting to mouse brain: mannose as a recognition marker.
F. Umezawa (1988)
Positive-charged solid lipid nanoparticles as paclitaxel drug delivery system in glioblastoma treatment.
D. Chirio (2014)
The epidemiology of glioma in adults: a "state of the science" review.
Q. Ostrom (2014)
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging
Sonu Bhaskar (2009)
Strategies for Enhanced Drug Delivery to the Central Nervous System
V. S. N. M. Dwibhashyam (2008)
Zero-valent Fe confined mesoporous silica nanocarriers (Fe(0) @ MCM-41) for targeting experimental orthotopic glioma in rats
M. Shevtsov (2016)
The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities
W. Carpenter (2008)
The 2007 WHO Classification of Tumours of the Central Nervous System
D. N. Louis (2007)
Biological Insights From 108 Schizophrenia-Associated Genetic Loci
S. Ripke (2014)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
K. Blennow (2010)
PSYCHOLOGICAL TRAINING AND COUNSELING FOR THE INCREASE OF PERSONNEL WELL-BEING AND FLIGHT SAFETY
Laura-Raluca Ştefan (2015)
Nanoparticle-Mediated Brain-Specific Drug Delivery, Imaging, and Diagnosis
H. Yang (2010)
Deregulated Signaling Pathways in Glioblastoma Multiforme: Molecular Mechanisms and Therapeutic Targets
H. Mao (2012)
Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid &bgr; After a Single Administration of an Amyloid &bgr; Monoclonal Antibody in Subjects With Alzheimer Disease
E. Siemers (2010)
Supported employment for people with severe mental illness: systematic review and meta-analysis of the international evidence.
M. Modini (2016)
Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns
T. Göppert (2005)
Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells
H. Sarin (2008)
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
M. Pangalos (2007)
Local carboxyfullerene protects cortical infarction in rat brain
A. Lin (2002)
In vivo Functional Evaluation of Increased Brain Delivery of the Opioid Peptide DAMGO by Glutathione-PEGylated Liposomes
A. Lindqvist (2015)
The Blood-Brain Barrier/Neurovascular Unit in Health and Disease
B. Hawkins (2005)
Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review.
Joana Bicker (2014)
Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment.
P. Chen (2010)
Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases
R. Gabathuler (2010)
SiO2 nanoparticles induce cytotoxicity and protein expression alteration in HaCaT cells
X. Yang (2009)
Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
C. Zhan (2010)
Stroke pathophysiology: management challenges and new treatment advances
J. Jordan (2009)
Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
R. Rosenheck (2011)
Methotrexate-incorporated polymeric nanoparticles of methoxy poly(ethylene glycol)-grafted chitosan.
Dong-hyuk Seo (2009)
Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
G. Choe (2002)
Dendrimers and other dendritic macromolecules: From building blocks to functional assemblies in nanoscience and nanotechnology
J. Fréchet (2003)
Transferrin-modified liposome promotes α-mangostin to penetrate the blood-brain barrier.
Zhi-lan Chen (2016)
CNS drug delivery systems: novel approaches.
S. A. Pathan (2009)
Cognition in schizophrenia: core psychological and neural mechanisms
D. Barch (2012)
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors.
E. Allard (2009)
Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
T. Golde (2016)
Innovative approaches for the development of antidepressant drugs: Current and future strategies
L. Schechter (2011)
Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
H. Chen (2011)
Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials
E. Liu (2015)
Epidemiology and the global burden of stroke.
D. Mukherjee (2011)
Effects of nanoparticle zinc oxide on spatial cognition and synaptic plasticity in mice with depressive-like behaviors
Yongling Xie (2011)
Association between genetic variant on chromosome 12p13 and stroke survival and recurrence: a one year prospective study in Taiwan
Yi-Chen Hsieh (2011)
Nanotechnological advances for the delivery of CNS therapeutics.
H. L. Wong (2012)
Neurotherapeutic applications of nanoparticles in Alzheimer's disease.
J. Sahni (2011)
Rural-urban migration and health: evidence from longitudinal data in Indonesia.
Yao Lu (2010)
Structure and function of the blood–brain barrier
N. Abbott (2010)
VEGF increases blood–brain barrier permeability to Evans blue dye and tetanus toxin fragment C but not adeno-associated virus in ALS mice
I. Ay (2008)
Active targeting of brain tumors using nanocarriers.
A. Béduneau (2007)
Nanoscale effects in dendrimer-mediated targeting of neuroinflammation.
Elizabeth A. Nance (2016)
Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization
Huile Gao (2013)
Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier.
R. Qiao (2012)
Convection-enhanced delivery of therapeutics for brain disease, and its optimization.
R. Raghavan (2006)
Development of a microfluidic based microvascular model: Towards a complete blood brain barrier (BBB) mimic
Luiza I. Genes-Hernandez (2008)
Prodrug approaches to reduce hyperexcitation in the CNS.
Devaiah Vytla (2012)
2016 Alzheimer's disease facts and figures
J. Gaugler (2016)
Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
Lucy Sanchez-Covarrubias (2014)
Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System
Huile Gao (2013)
The epidemiology of depression across cultures.
R. Kessler (2013)
An update on potential therapeutic strategies for Parkinson’s disease based on pathogenic mechanisms
T. Shen (2016)
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
J. Kanwar (2012)
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs.
E. Dale (2015)
Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles
K. B. Kurakhmaeva (2009)
Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects.
S. Haijma (2013)
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
T. Taylor (2012)
Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier*
C. Fillebeen (1999)
Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders.
J. Ting (2012)
Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles.
N. Sheikov (2004)
Microencapsulation : Methods and Industrial Applications, Second Edition
S. Benita (2005)
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
M. Fazil (2012)
Phase I Study of NK012, a Novel SN-38–Incorporating Micellar Nanoparticle, in Adult Patients with Solid Tumors
T. Hamaguchi (2010)
Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
Z. Wang (2010)
Lipid-based nanocarriers for CNS-targeted drug delivery.
Maria-Rita Micheli (2012)
The effectiveness of a magnetic nanoparticle-based delivery system for BCNU in the treatment of gliomas.
M. Hua (2011)
Microencapsulation : methods and industrial applications
S. Benita (1996)
Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain.
I. van Rooy (2011)
Drug Delivery to the Brain
W. Pardridge (1997)
Genetic pathways to primary and secondary glioblastoma.
H. Ohgaki (2007)
Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy.
P. Zhang (2012)
Minimally invasive molecular delivery into the brain using optical modulation of vascular permeability
Myunghwan Choi (2011)
Junctional complexes of the blood–brain barrier: permeability changes in neuroinflammation
M. Petty (2002)
Epidemiology and molecular pathology of glioma
Judith A Schwartzbaum (2006)
CHLAMYDIA PNEUMONIAE-INFECTED ASTROCYTES ALTER THEIR EXPRESSION OF ADAM10, BACE1, AND PRESENILIN-1 PROTEASES
Zein Al-Atrache (2016)